Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium

Craig S Smith1, Paul A Bottomley, Steven P Schulman

  • 1Department of Medicine, Cardiology Division, The Johns Hopkins Hospital, Baltimore, MD 21287-6568, USA. rweiss@jhmi.edu

Circulation
|September 6, 2006
PubMed

Insights

In patients with left ventricular hypertrophy (LVH), impaired adenosine triphosphate (ATP) turnover kinetics through creatine kinase (CK) is a key factor in the progression to chronic heart failure (CHF). This energy deficit, not metabolite levels, distinguishes failing from non-failing hypertrophic hearts.

Area of Science:

  • Cardiology
  • Biochemistry
  • Physiology

Background:

  • Pressure-overload left ventricular hypertrophy (LVH) can progress to chronic heart failure (CHF).
  • A potential mechanism involves impaired myocardial energy supply or delivery.
  • Creatine kinase (CK) is crucial for maintaining cardiac energy reserves.

Purpose of the Study:

  • To investigate if adenosine triphosphate (ATP) flux through CK is impaired in patients with LVH and CHF.
  • To compare CK metabolite concentrations and kinetics between normal subjects, LVH patients, and LVH+CHF patients.

Main Methods:

  • Measurement of myocardial CK metabolite concentrations (ATP, creatine phosphate).
  • Assessment of ATP synthesis and CK pseudo first-order rate constant.
  • Comparison of these parameters across three groups: normal (n=14), LVH (n=10), and LVH+CHF (n=10).

Main Results:

  • Myocardial ATP levels were normal in LVH and LVH+CHF patients.
  • Creatine phosphate levels were reduced by 35% in LVH patients compared to normal subjects.
  • The CK pseudo first-order rate constant was halved in LVH+CHF patients.
  • Net ATP flux through CK was significantly reduced by 30% in LVH and 65% in LVH+CHF compared to normal subjects.

Conclusions:

  • Impaired ATP turnover kinetics through CK, not metabolite pool sizes, differentiates failing from non-failing hypertrophic hearts.
  • The deficit in ATP kinetics is linked to the presence of CHF, not the severity of hypertrophy.
  • Reduced ATP kinetics suggests a deficit in myofibrillar energy delivery contributing to CHF pathophysiology in LVH.
Abstract

Related Concept Videos

Muscle Recovery and Fatigue01:24

Muscle Recovery and Fatigue

Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective response...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...